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Abstract  
In vitro manipulation of membrane sterol level affects the regulation of ion channels and consequently 
certain cellular functions, however, a comprehensive study that confirms the pathophysiological 
significance of these results is missing. The malfunction of 7-dehydrocholesterol (7DHC) reductase in 
Smith-Lemli-Opitz syndrome (SLOS) leads to the elevation of the 7-dehydrocholesterol level in the 
plasma membrane. T lymphocytes were isolated from SLOS patients to assess the effect of the in vivo 
altered membrane sterol composition on the operation of the voltage-gated Kv1.3 channel and the ion 
channel-dependent mitogenic responses. We found that the kinetic and equilibrium parameters of Kv1.3 
activation changed in SLOS cells. Identical changes in Kv1.3 operation were observed when 
control/healthy T cells were loaded with 7DHC. Removal of the putative sterol binding sites on Kv1.3 
resulted in a phenotype that was not influenced by the elevation in membrane sterol level. Functional 
assays exhibited impaired activation and proliferation rate of T cells probably partially due to the modified 
Kv1.3 operation. We concluded that the altered membrane sterol composition hindered the operation of 
Kv1.3 as well as the ion channel-controlled T cell functions.  
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Introduction 
Cholesterol (CHOL) is a crucial component of the mammalian plasma membrane, it determines the 
biophysical properties of the lipid bilayer as well as the function of the embedded proteins. CHOL 
homeostasis of the mammalian cells is strictly regulated by complex mechanisms (51). In the last decades 
numerous malformation syndromes have been associated with the inborn error of the CHOL synthesis 
(reviewed in (46)). The link between reduced CHOL synthesis and a serious health condition was 
described first for the Smith-Lemli-Opitz syndrome (SLOS) (29, 59, 65). The SLOS phenotypic spectrum 
is very broad, ranging from a mild disorder with behavioral and learning problems to a lethal 
malformation syndrome (incidence of SLOS is 1 in 39,000 births (17)) (45, 46). The disease is 
characterized by the constellation of severe birth defects affecting multiple organ systems (central nervous 
system, cardiac, pulmonoray, gastrointestinal). Craniofacial features (microcephaly, a small upturned 
nose, ptosis and micrognathia) and the syndactily of the second and third toes are the most frequent 
physical manifestations of SLOS. Growth failure and feeding problems are also common in SLOS. 
Moreover, many SLOS infants have behaviour problems (autism, hyperactivity, self-injures 
behaviour).(45, 46) Irons and his colleagues showed that the SLOS is caused by the deficiency of 7-
dehyrocholesterol-reductase (DHCR7), which catalyzes the last step in the CHOL biosynthetic pathway 
(29). Altered DHCR7 activity led to increased 7DHC and reduced CHOL levels both in the serum and in 
the plasma membrane of fibroblasts and erythrocytes (16, 61).The severity of the disease and life 
expectancy of the patients is mostly determined by initial serum CHOL level, while the ratio of 
7DHC/CHOL has an additional prognostic value (5). Oral cholesterol and simvastatin administration are 
used in the treatment of SLOS, however, retrospective studies did not confirm its effectiveness (12, 19, 24, 
58).  
Ion channels are pore-forming, integral membrane proteins allowing the transport of inorganic 
ions down their electrochemical gradient across the cell membrane. Voltage-gated potassium channels (Kv 
channels) are the largest and most diverse group of the ion channels including up to 40 members (23). 
They are composed of four, generally identical -subunits, each of which is composed of six 
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transmembrane domains (S1-S6) connected by extra- and intracellular loops. S5 and S6 segments with the 
pore loop between them form the pore domain (PD) of the channel which includes the ion conducting 
pore, whereas S1-S4 and the positively charged amino acids in S4 make up the voltage-sensing domain 
(VSD). Kv1.3, which belongs to the Shaker subfamily of Kv channels, is the predominant voltage-gated 
K
+ 
channel of human T lymphocytes (18, 39).The main function of Kv1.3 channels during T cell 
activation is the maintenance of a permissive membrane potential (−50 mV) required for appropriate 
extracellular Ca
2+
 entry and proper Ca
2+
 signaling. By the use of Kv1.3-selective antagonists, lymphocyte 
proliferation and IL-2 production can be inhibited (14, 47). It has been reported earlier by several labs that 
CHOL is a significant regulator of various types of ion channels including Kv1.3 (27, 49, 52). Generally, 
the excess CHOL content of the plasma membrane suppresses the ion channel activity by reducing the 
open probability or conductivity. These suppressing effects were shown not only for Kv channels but for 
Ca
2+
 and Na
+
 channels as well (33). On the other hand, some of the channels (e.g. TRPV channels and 
ENaC (33)) have been referred to as CHOL-dependent, whereby CHOL depletion reduces the activity of 
the channels. We showed earlier that the CHOL loading of T cell membrane significantly slowed the 
activation and inactivation kinetics of Kv1.3 and modified the parameters of the steady-state activation 
(27).  
It was demonstrated that 7DHC can incorporate into biomembranes and SLOS patients have an 
increased 7DHC level in the plasma membrane (61). Moreover, accumulation of the 7DHC in the plasma 
membrane can affect the physical-chemical behavior of the lipid bilayer, and also influence the function of 
membrane proteins by disrupting/modifying the raft structure and/or interacting directly with the proteins 
themselves (11, 30, 61). The single-channel conductance of the BKCa channel, which co-localizes with 
caveolin in CHOL-rich membrane domains, is reduced and the voltage-dependence of the open 
probability is right-shifted in SLOS fibroblasts (48). The function of Na
+
/K
+
 ATPase is also decreased in 
SLOS fibroblast (48). 
To our knowledge there are no other reports, in which the altered biophysical parameters of a Kv 
channel and its functional consequences are demonstrated in cells isolated from SLOS subjects. Here we 
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demonstrate that the operation of Kv1.3 channels, which are also expressed in neuronal cells, is modified 
in T cells of SLOS patients as compared to healthy age-matched control. We have found that changes in 
the gating of Kv1.3 channels in SLOS lymphocytes were similar to those recorded in control T cells 
loaded with 7DHC using methyl-β-cyclodextrin/7DHC complex. Removal of the C-terminal end of Kv1.3 
abolished the sterol sensitivity of Kv1.3, which proves interaction between the channel and membrane 
sterols. Furthermore, the modified operation of Kv1.3 in the SLOS T cells was associated with impaired 
proliferation rate and a defect in the early steps of Kv1.3- and Ca
2+
-dependent activation pathway in CD3
+
 
T cells. We propose that the ion channel-sterol interaction described in our study reveals a molecular 
mechanism that may contribute to various  pathophysiological conditions via influencing the physiological 
function of ion channels. 
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Material and methods 
Patients 
All eight SLOS patients who were accessible in Hungary (age: 7.65±2.23 years) and eight age-matched 
control patients from Hungary (age: 7.66±1.83 years) were enrolled in the study. On the basis of clinical 
severity score, patients were assigned to three groups: score below 20 means mild disease, while typical 
SLOS patients have a score between 20 and 50, and above 50 the severe type of SLOS is manifested (5, 
41).Three of the patients were characterized with mild disease (age: 9±1.88 years, serum 7DHC 0.38±0.08 
mmol/l, serum CHOL was 2.64±0.36 mmol/l), and five children with typical disease (age: 7.4±2.13 years, 
mean serum7DHC and CHOL level was 0.5±0.09 mmol/l and 1.44 ± 0.26 mmol/l, respectively). After 
setting up the diagnosis, all of the enrolled patients received dietary CHOL substitution (56). Statin 
therapy was also started after diagnosis but in case of two patients it was suspended because of elevated 
liver enzymes. Informed consent was obtained from all individual participants included in the study.  
Human blood was obtained following a protocol approved by the Institutional Review Board of University 
of Debrecen. All procedures performed in studies involving human participants were in accordance with 
the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its 
later amendments or comparable ethical standards.  
 
Cells 
Five ml heparinized human peripheral venous blood was drawn from SLOS patients and healthy control 
children. Mononuclear cells were separated by Ficoll-Hypaque density gradient centrifugation. Freshly 
isolated cells were used for CFSE-assay and the remaining mononuclear cells were frozen and stored at -
80 
o
C until patch-clamp and CD154 expression experiments. Following CFSE staining (see below) and 
activation, cells were cultured in 24 or 96 well plates at a cell density of 10
6
 cells/ml in standard RMPI-
1640 medium (Sigma-Aldrich Co., Saint Louis, MO, USA) containing 15 mM HEPES buffer (Sigma-
Aldrich Co., St. Louis, MO, USA) at 37°C in humid atmosphere with 5% CO2. CHO cells (ATCC, 
Germany) were cultured in DMEM medium (Sigma-Aldrich), which also contained 10 % FBS, L-
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glutamine (2 mM), penicillin (100U/l), and streptomycin (100 mg/l). Cells were maintained at 37 °C in a 
humidified atmosphere of 5% of CO2 and 95% air. Cells were passed every 2–3 days. CHO cells were 
transduced with retroviral particles containing mGFP-Kv1.3-WT and mGFP-Kv1.3ΔC constructs as 
described in (57).  
 
Analysis of the sterol composition of red blood cells using GC-MS 
Gas chromatography-mass spectrometry (GC-MS) experiments were carried out by use of the standard 
protocols. Before extraction ergosterol, as internal standard for sterol quantitation was added to the 
homogenates (10 μg/protein mg). Lipids were extracted according to a modified Folch procedure as 
described in (4). Protein content of cell homogenates was determined with the BCA protein assay kit 
(Thermo Scientific) using the protocol recommended by the manufacturer. Quantitative analysis of CHOL 
and 7DHC was carried out by a GC-MS system (GCMS-QP2010, Shimadzu) equipped with a BPX-1 
capillary column (10 m×0.1 mm×0.1 μm film thickness). An aliquot of the extracts (corresponding to 50 
μg protein) was evaporated, the residue redissolved in 25 μl benzene followed by addition of 3 μl N,O-
bis(trimethylsilyl)acetamide and kept at room temperature for an hour. A 1-μl aliquot of the resulting 
trimethylsilyl ether derivative of the different sterols was injected onto the column programmed at 30 
°C/min from 150 to 290 °C, and maintained isothermally for 3 min. Identification was made based on 
CHOL and 7DHC standard solutions. Quantization was carried out by comparison to ergosterol standard. 
 
Electrophysiology 
Whole-cell measurements were carried out using Axopatch-200A/B amplifiers connected to personal 
computers using Axon Digidata 1440 digitizers. For data acquisition and analysis the pClamp10 software 
package (Molecular Devices, Sunnyvale, CA) were used. CD4
+
T lymphocytes were selected for current 
recording by incubation with mouse anti-human CD4 antibodies (0.5 µg/106 cells, AMAC, Westbrook), 
followed by selective adhesion to petri dishes coated with goat anti-mouse IgG antibody (Biosource, 
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Camarilo, CA), as described previously (39). Standard whole-cell patch-clamp techniques were used, as 
described previously (28). Pipettes were pulled from GC 150 F-15 borosilicate glass capillaries (Clark 
Biomedical Instruments, UK) in four stages and fire-polished to give electrodes of 3–6 M resistance in 
the bath. The standard bath solution (S-ECS) was (in mM): 145 NaCl, 5 KCl, 1 MgCl2, 2.5 CaCl2, 5.5 
glucose, 10 HEPES (pH 7.35, 305 mOsm). The pipette solution was (in mM): 140 KF, 11 K2EGTA, 1 
CaCl2, 2 MgCl2, and10 HEPES (pH 7.20,295 mOsm). To study activation kinetics of Kv1.3 T cells were 
depolarized to 50 mV for 15 or 30 ms from a holding potential –120mV. Kv1.3 current traces were fitted 
with a single exponential function rising to the maximum according to the Hodgkin-Huxley model (I(t) = 
Ia (1exp(t/a))
4
 + C, where Ia is the amplitude of the activating curve component;a is the activation 
time constant of the current; C: current amplitude at –120 mV). The activation time constant for a 
particular cell was defined as the average of time constants obtained for at least 3 depolarizing pulses 
repeated at every 15 s in a sequence. We recorded at least four cells of a given patient or donor, and the 
average of the activation time constants was used to demonstrate the activation kinetics of control and 
SLOS groups. To study the inactivation of Kv1.3 channels, two-second-long step pulses to +40 mV from a 
holding of -120 mV were applied to the cells. The fast activation of outward current is followed by a 
relatively slow decay of current corresponding to the C-type inactivation of this channel. The decaying 
part of the current traces was fitted with a single exponential function (I(t) = I0 exp(-t/in,i) + C, I0: 
amplitude of current,𝜏in,i: inactivation time constant for different groups, C: steady-state value of whole-
cell current at the end of the pulse) to attain the time constant characterizing the inactivation kinetics. The 
characteristic inactivation time constant for a given cell was determined as detailed for the activation 
kinetics. Membrane potential dependence of steady-state activation of the Kv1.3 current was determined 
as follows: cells were held at 120 mV and depolarized to gradually increasing test potentials. Peak 
whole-cell conductance (G(V)) at each test potential was calculated from the peak current (Ipeak) at a test 
potential V and the K
+
 reversal potential (EK) using G(V) = Ipeak/(Vtest-Er). The G(V) values were 
normalized for the maximum conductance (Gnorm) and plotted as a function of test potential along with the 
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best-fit Boltzmann function (Gnorm = 1/(1+exp [ (VV½)/k], where Gnorm is the normalized conductance, V 
is the test potential, V½is the midpoint and k is the slope of the function). We calculated the steady-state 
parameters at least four individual cells from each donor. The whole-cell membrane capacitance (C) 
setting on the amplifier required to cancel the transient charging currents evoked by periodic application 
of 5mV test pulses was considered as the membrane capacitance of the cells. 
 
7DHC and CHOL loading of T cell membrane 
Freshly isolated control (healthy) lymphocytes were washed twice with Hanks’ solution and suspended in 
Hanks’ solution (2 × 106 cells/ml) containing different concentrations of methyl--cyclodextrin/7-DHC 
(MCD/7DHC, kind gift of Lajos Szente, CycloLab Cyclodextrin Research and Development Laboratory 
Ltd. , Hungary) or methyl--cyclodextrin/CHOL (MCD/C, CycloLab Cyclodextrin Research and 
Development Laboratory Ltd. , Hungary). In control experiments MCD/7DHC, MCD/C was not 
present in the solution. Cell suspensions were incubated for 1 h at 37 
o
C and washed three times with 
Hanks’ solution. 
 
CD154 expression detection 
Previously isolated control and SLOS mononuclear cells were stimulated with thapsigargin (1 µM) for 3 
hours at 37C. For flow cytometry, cells were labeled with phycoerythrin conjugated mouse anti-CD3 
antibody (PE-CD3) and Alexa-488 conjugated mouse anti-CD154 antibody (A488-CD154) and there 
isotype control for 20 minutes at room temperature according to the manufacturer’s protocol (Biolegend; 
San Diego; CA). After the staining procedure, the fluorescence intensity of T cells was assessed by BD 
FacsScan flow cytometer (Beckton-Dickinson, NJ, USA). In all experiments, at least 10000 events were 
recorded and analyzed using FCS Express 4 software. Dead cells were excluded by gating based on side 
and forward scatter. 
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CFSE staining and analysis  
To study proliferation of lymphocytes, we applied the modified version of carboxyfluorescein 
succinimidyl ester (CFSE) dilution essay, originally described by Lyons et al (36-38, 43).The final 
concentration of CFDA-SE (CellTrace™ CFSE Cell Proliferation Kit, Life Technologies Co., Waltham, 
MA, USA) was 1µM that provided a 100- to1000-fold increase in the fluorescence intensity of the loaded 
cells compared to the autofluorescence of unstained cells.. We applied 500 ng/ml soluble anti-CD3 
antibodies combined with 1 µg/ml soluble mouse anti-human CD28 (Sigma-Aldrich Co., Saint Louis, 
MO, USA) for specific T cell stimulation in the mononuclear cell cultures. The flow cytometry analysis 
was performed on a BD FACScan™ cytometer. Fluorescence gate settings for lymphocytes are shown on 
Figure 7a and 7b. Lymphocytes were selected from mixed cell populations of PBMC by their light scatter 
profile on FACS analysis (7a). Cell proliferation was determined based on the decreasing CFSE intensity 
in the green channel (Figure 7c). The indicator of proliferation was the division index (DI), calculated by 
the formula: 
𝐷𝐼 = (∑𝐴𝑘
𝑛
𝑘=1
)/(∑𝐴𝑘
𝑛
𝑘=0
) 
where k points to the n
th
 generation of cells, and Ak is the cell number in the k
th
 division cycle according to 
Figure 7c.  
 
 
Data analysis 
 Prior to analysis whole-cell current traces were corrected for ohmic leak. Non-linear least squares 
fits were done using the Levenberg-Marquardt algorithm. Fits were evaluated visually as well as by the 
residuals and the sum of squared differences between the measured and calculated data points. Data are 
expressed as mean ± SEM. For pairwise comparisons Student's t-test or Mann–Whitney rank sum test 
(non-normal distribution population) were applied. For multiple comparisons one-way or two-way 
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ANOVA with post-hoc Holm-Sidak (HS) test were used. Statistical significance was taken as p<0.05 (* 
indicates statistical difference) or p<0.001 (** indicates statistical difference). 
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Results 
Sterol composition of SLOS membrane 
We characterized the sterol profile of the red blood cells (RBC) from SLOS patients and age-matched 
control donors in order to gain information regarding the alteration of the sterol environment, and  
especially that of the 7DHC/CHOL ratio in the cell membrane induced by the SLOS disease (16, 61). 
Table 1 shows the elevated 7DHC and reduced CHOL levels in all of the SLOS samples, while 7DHC in 
the control samples was undetectable. 8DHC, which is a common isomer of 7DHC, was also identified in 
every SLOS sample (data not shown) (8). Results of the RBC sterol composition analysis are comparable 
to the comprehensive study by Russo et al. (16).  
 
Expression level of Kv1.3 channels in SLOS T cells is similar to that in healthy donors  
Since Kv1.3 channel is the main voltage-gated K
+
 channel of T lymphocytes and plays pivotal role in 
regulating of the proliferation of T cells, we examined the expression and biophysical properties of Kv1.3 
channels in SLOS patients. Current density (CuD: the peak current normalized to membrane capacitance, 
proportional to the number of channels per unit area) provides information about the impact of the 
channels on the membrane potential control of the cell, since a given number of channels regulate the 
membrane potential more readily in a smaller cell than in a larger one. T cells were held at –120 mV 
(holding potential) and depolarized to +50 mV for 15 ms in whole-cell configuration to determine whole 
cell peak currents (Ip), then Ip of an individual cell was divided by the membrane capacitance (C) of the 
particular cell to calculate current density. Whole-cell peak currents and whole-cell membrane capacitance 
were the same in control and SLOS groups, and there was no statistical significant difference between the 
current densities of control and SLOS T cells (see Figure1 and Table 2.). 
 
Slowing of Kv1.3 current kinetics in SLOS T cells 
We previously demonstrated that the increase of CHOL content of the T-cell membrane influenced the 
gating kinetics of Kv1.3 (27). To study whether the altered sterol profile in SLOS affects the kinetic 
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properties of Kv1.3 current, we recorded Kv1.3 whole-cell currents of T lymphocytes isolated from SLOS 
patients and control (age-matched healthy) donors. Figure 2a shows normalized current traces evoked in a 
control and an SLOS T lymphocyte upon depolarization to +50 mV. The activation time constant (a), (see 
Materials and Methods) was significantly greater for SLOS cells, i.e. the kinetics of channel opening is 
slower in SLOS lymphocytes (Figure 2a, d and Table 2.). Figure 2b illustrates normalized current traces 
recorded during 2-second-long step pulses to +40 mV: the fast rising of the current is followed by a 
relatively slow decay, which corresponds to the C-type inactivation of Kv1.3 channels. By fitting a single-
exponential function to the declining part of these curves, we obtained the inactivation time constants (see 
Materials and Methods), which did not show significant increase (Figure 2e and Table 2.).  
 
SLOS modifies the membrane potential-dependence of steady-state activation  
As the kinetics of the Kv1.3 gating was affected by the increased 7DHC level, we also investigated the 
equilibrium parameters of Kv1.3 activation. Fig. 2c displays Gnorm-V plots for an SLOS and a control T 
cell along with the best-fit Boltzmann curves (for details see Materials and methods): the sigmoid curve of 
the voltage-dependence of steady-state activation for SLOS patient is rightward shifted as compared to the 
control (Figure 2c). Comparison of the equilibrium activation parameters showed that the midpoint of the 
curve (V1/2, the membrane potential at which 50% of the channels is open at  steady-state) is significantly 
more positive for SLOS T cells without a statistically significant change in the slope factor (Figure 2f and 
Table 2.). 
 
Modeling 7DCH/CHOL ratio of the SLOS membrane in T cell 
To verify if 7DHC incorporation into the T cell membrane affects Kv1.3 function, we created an SLOS-
like sterol environment by modification of the 7DHC content of healthy T cells with MβCD/7DHC 
complex in vitro. To validate the incorporation of 7DHC into the plasma membrane, untreated and 
MβCD/7DHC treated PBMCs were subjected to GC-MS analysis. Fig. 3a shows that the amount of 7DHC 
in the cell membrane increases gradually with the higher applied concentration of MβCD/7DHC (7DHC 
14 
 
level normalized to protein content was 26.1 ± 1.0 g/mg for 65M MCD/7DHC and 66.8 ± 11 g/mg 
for 195M MCD/7DHC). Parallel to the increase in MβCD/7DHC, the CHOL content showed 
decreasing tendency, which can be due to the CHOL removal by the empty MβCD, but the change was 
not significant as compared to the untreated group (CHOL level normalized to protein amount was 18.3 ± 
3.7g/mg for control, 16.2 ± 0.2 g/mg for 65M MCD/7DHC; 13.3±2 g/mg for 195M 
MCD/7DHC). These clearly showed that membrane 7DHC and CHOL ratio is similar to those described 
in SLOS patients. 
 
Biophysical properties of Kv1.3 in 7DHC-loaded T cells resemble those observed in SLOS 
Next we characterized the kinetic and equilibrium parameters of Kv1.3 gating in the 7DHC-loaded CD4
+
 
T cells. First, the activation kinetics of Kv1.3 channels was measured for 7DHC-loaded cells and we 
found that activation kinetics became slower as the 7DHC level increased in the membrane (Figures 3b 
and d, Table 3). For the inactivation kinetics, we found that the time constant increased compared to 
untreated cells (Table 3). Finally, the voltage-dependence of steady-state activation was evaluated for T 
cells treated with different amounts of MβCD/7DHC: just as described for SLOS cells, the midpoint of 
activation, i.e. the half-maximal voltage was shifted to the positive voltages (Figure 3c, e and Table 3) but 
slope factor did not change (Figure 3e, Table 3) . These data together suggest that the change of the 
membrane 7DHC content can be responsible for the altered Kv1.3 function in SLOS. Current density, 
whole-cell peak current and membrane capacitance were also determined for 32.5, 65, and 195 M 
MCD/7DHC treatments. Although membrane capacitance did not change, the whole-cell peak currents 
decreased significantly upon the 7DHC loading (Table 3). Consequently, the MCD/7DHC loading 
significantly decreased the current density of Kv1.3 of T cells unlike for those from the SLOS patients 
(Figure 3f and Table 3).  
 
Comparison of CHOL and 7DHC loading 
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In our previous study we demonstrated that in vitro loading of CHOL slowed the kinetics and 
modified the steady-state parameters of Kv1.3 gating. Similar changes in the biophysical parameters of 
Kv1.3 gating were found in the current study in SLOS and SLOS model system (26). These results raised 
the question whether the effect of 7DHC and CHOL loading are quantitatively similar or different. 
Therefore, we treated the T cells with the same concentration of CHOL and 7DHC and measured the 
biophysical properties of Kv1.3. We found that Kv1.3 is more sensitive to 7DHC than CHOL loading at 
32.5µM: 7DHC significantly increased the activation time constant and shifted V1/2 towards positive 
voltages, whereas CHOL did not (Figures 4a, d and Table 3). At higher concentrations of MCD/7DHC 
and MCD/CHOL both compounds changed the kinetic and steady-state parameters of Kv1.3 gating but 
195 µM MCD/7DHC was more effective in changing V1/2 than equimolar MCD/CHOL (Figures 4b, c, 
e, f and Table 3.). Our results suggest that CHOL and 7DHC influence channel function in a very similar 
way, however, due to their structural difference their capacity to modify the operation of an ion channel 
could be distinctive. 
Removal of the cytoplasmic C-terminal of Kv1.3: loss of sensitivity to sterol loading 
We tested the effect of CHOL and 7DHC loading on a C-terminal-deleted Kv1.3 channel (mGFP-
Kv1.3ΔC), which lacks the last 84 amino acid residues at its C-terminal and consequently lacks the two 
CARC sequences recently identified on other ion channels as specific CHOL receptor sites being 
responsible for the effect of sterols on ion channels (20, 34, 49, 52). If CHOL and 7DHC acts on these 
proposed receptor sites then Kv1.3ΔC should be CHOL and 7DHC insensitive.  Previously we showed 
that biophysical characteristics of the mGFP-Kv1.3-WT and mGFP-Kv1.3ΔC are identical, removal of the 
C-terminal did not change significantly the gating properties of Kv1.3 (57). mGFP-Kv1.3-WT and mGFP-
Kv1.3ΔC expressing CHO cells were loaded using 420M CHOL and 7DHC, and ionic currents were 
measured in outside-out patch configuration. As expected 420M CHOL or 7DHC shifted the midpoint of 
the voltage-dependence of steady-state activation and increased the activation time constant in case of the 
mGFP-Kv1.3-WT CHO cells (V1/2,WT: −28.9±1.5 for control and −17.5±1.9 mV for 420 M CHOL, 
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p<0.001; −19.3±4.7 mV, p = 0.028 for 420 M 7DHC; a,WT: 0.45±0.01 ms for control, 0.76 ± 0.02 ms for 
420 M MCD/CHOL, p = 0.002; 0.69 ±0.06 ms for 420M MCD/7DHC, p = 0.008, Figures 5a and c.) 
On the contrary, mGFP-Kv1.3ΔC channels were insensitive to both CHOL and 7DHC loading 
(V1/2,ΔC:−26.7±2.7 mV for control; V1/2,ΔC:−26.3±2.7 mV for 420 M MCD/CHOL, p>0.05; V1/2,ΔC: 
−23.1±1.1 mV for 420 M MCD/7DHC, p>0.05); and a,ΔC: 0.59±0.04 ms for control, 0.55±0.02 ms for 
420M MCD/CHOL, p>0.05; 0.65±0.04 ms for 420M MCD/7DHC, p>0.05, Figures 5b and d). 
 
Activation and proliferation of SLOS T cells is suppressed 
We aimed to study the effects of the altered 7DHC/CHOL ratio on the Kv1.3-dependent biological 
functions of T cells such as activation and proliferation. To assess the effect of SLOS on T cell activation, 
we measured the expression of CD154 of lymphocytes. CD154 is a marker of activation on T lymphocytes 
stimulated through calcium-triggered NFAT pathways (1, 6). We assumed that the modified ion channel 
function in SLOS influences the Kv1.3-dependent calcium signaling during T cell activation, which could 
change the expression of CD154. Mononuclear cells were stimulated with thapsigargin to trigger the 
calcium-dependent activation pathway and labeled with PE-conjugated anti-CD3 and A488-conjugated 
anti-CD154 antibody. T cells were identified by gating on CD3
+
 cells (Fig. 6a and b). Our results indicate 
that the ratio of CD154
+
  T cells decreased significantly in SLOS compared to the age-matched healthy 
controls (fraction of CD154
+
CD3
+cells in SLOS:  8.6 ± 3.2%, control: 21.1 ±2.8%, Figure 6c and d, 
p<0.001). The mean fluorescence intensity (MFI) of SLOS lymphocytes was also reduced, but the 
difference was not significant (MFI of CD154 in SLOS: 15.5 ± 2.1 a.u. ; in control group: 20.4 ± 3.7 a.u., 
p = 0.13). We also tested the proliferation capacity of T cells using the CFSE staining technique, which is 
a suitable method to observe the proliferation characteristics of lymphocytes with flow cytometry (Figure 
7a and b).We found that the five-day antiCD3/antiCD28 stimulation (see details in Materials and 
Methods) of T lymphocytes was less effective in SLOS than in the control group (Figures 7c and d). The 
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division indices of T lymphocytes were 29.4 ± 3.5% and 61.1 ± 7.1 % for SLOS and the control group, 
respectively (p = 0.002, Figure 7e). 
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Discussion 
In the present study we reported for the first time that accumulation of 7DHC in the cell 
membrane modifies the operation of the voltage-gated ion channel Kv1.3 both in SLOS T cells and in T 
cells acutely loaded with 7DHC (MCD/7DHC-treated lymphocytes), and also influences the Ca2+-
dependent signaling events coupled to Kv1.3 activity. We showed that 1) elevated membrane 7DHC level 
in SLOS T cells modifies the equilibrium and kinetic properties of Kv1.3 activation, 2) MCD/7DHC 
loading of T cell membrane, which mimics the sterol environment in SLOS, results in similar changes in 
Kv1.3 gating as described in SLOS, 3) the Kv1.3 construct (Kv1.3C)  lacking the putative sterol-binding 
sequences on the C-terminus is insensitive to the sterol-modification of the membrane, 4) the early steps 
of the Ca
2+
-dependent T cell activation pathway as well as the division index of  SLOS T cells is 
hampered. These data all support that presence of 7DHC in the plasma membrane affects Kv1.3 function 
and the cellular processes which depend on Kv1.3 activity.  
The laboratory medicine profile (i.e. serum sterols) of SLOS patients is quite diverse, a wide range 
of plasma 7DHC and CHOL concentrations were reported even for genetically homogenous patient 
groups (16, 42).  Furthermore, the 7DHC/CHOL ratios in the plasma and in red blood cells also show 
significant variations among patients. Therefore, we aimed at confirming that cellular 7DHC to CHOL 
ratios display 7DHC accumulation in our patient group. In the absence of sufficient amount of blood 
samples for the characterization of the sterol composition of the T cell membrane we monitored the 7DHC 
content as well as the ratio of CHOL/7DHC in RBCs isolated from SLOS patients (Table 1). Our data 
confirmed a decrease in CHOL and increase in 7DHC levels in the RBCs of every donor (see Table 1) as 
compared to healthy counterparts. Moreover, manipulation of the sterol level of T cell membranes with 
MCD/7DHC complex clearly indicated an elevation of 7DHC level, while the CHOL content reduced 
mildly (Figure 3a). We are aware that 7DHC enrichment of the T cell membrane using MCD and the 
consequent altered ratio of 7DHC/CHOL only partly mimics the SLOS plasma membrane. For example 
other species of CHOL precursors and 7DHC-derived oxysterols were not present in the T cells treated 
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with MCD complexed to CHOL or 7DHC whereas these compounds are identified in SLOS cells (7, 8, 
66, 67). Nevertheless, 7DHC is the prominent sterol in the SLOS membrane and the biophysical 
parameters of Kv1.3 gating were similarly affected in SLOS and in T cells treated with MCD/7DHC 
complex. This suggests that acute loading of T cells with 7DHC mimics adequately the effect of the lipid 
milieu existing in SLOS on the operation of Kv1.3 (11, 29, 30, 54, 68). 
We showed clearly that the voltage-dependence of steady-state activation of Kv1.3 is shifted to 
more depolarized potentials in SLOS T cells as compared to age-matched control T cells. However, the 
shift in the V1/2 is relatively small in SLOS T cells as compared to T cells treated with MCD/7DHC. This 
could be explained by the heterogeneity of the patient group regarding 7DHC levels, 7DHC/CHOL ratio 
or the severity of the disease. Nevertheless, the very clear and monotonic dose-dependence of the 
activation time constant and the V1/2 on the MCD/7DHC concentration (Figure 3) suggests that the gating 
parameters of Kv1.3 are qualitatively and quantitatively related to 7DHC loading of the cells. Here we 
would also note that we could not identify a correlation between the 7DHC level (or 7DHC/CHOL ratio) 
and the extent of the change in Kv1.3 biophysical parameters in SLOS T cells. This latter may be 
explained by the low number of donors included in this study.  
Our experiments also addressed an obvious question: how does the altered membrane sterol composition 
impair the gating of Kv1.3 in SLOS? According to the current theories sterols and ion channels can 
interact directly or membrane sterols can affect the operation of ion channels by influencing the 
biophysical properties of the cell membrane (membrane fluidity, membrane compartmentalization) (11, 
20, 34). Strong pieces of evidence support both theories and these two models are not mutually exclusive. 
The effect of 7DHC on the biophysical properties of the cell membrane is contradictory. For example, it 
has been demonstrated that 7DHC destabilizes cholesterol rich domains, increases the membrane fluidity 
and alters the protein pattern of rafts (11, 30, 61). On the contrary, according to Liu et al, the difference 
between CHOL and 7DHC from the perspective of membrane ordering and condensation is essentially 
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imperceptible (35). All in all, we can’t exclude the possibility of the indirect regulatory effect of 7DHC on 
Kv1.3 gating.  
On the other hand, CHOL is a prominent component of the annular lipid belt around the 
transmembrane segment of ion channels thereby stabilizing the conformation of the channel (33). It seems 
that VSD’s and not the pore domain of Kv channels require the lipid belt (50). Recent structure-function 
studies show that the VSD’s of Kv1.2 are positioned at the corners of the square shaped PD creating deep 
grooves between the adjacent subunits. These grooves are expected to be filled with lipids whose ordering 
may be different than the rest of the membrane, generating optimal environment for specific lipid-protein 
interactions (60). In SLOS 7DHC substitutes CHOL in the cell membrane and may impair direct CHOL-
protein interactions of annular lipids which may result in altered operation of the VSD’s.  
As for the specific CHOL-ion channel interaction, several CHOL binding motifs of the membrane 
and intracellular proteins have been described in the literature recently (CRAC, CARC and CCM motif), 
which serve as specific CHOL receptor sites (20, 34). Due to the low stringency requirements for the 
amino acid pattern of these motifs should be accepted with careful skepticism but it is notable that a 
simple point mutation or deletion of these selected motifs could totally abolish CHOL sensitivity of ion 
channels (44, 49, 52). Based on the work of Dopico et al. we identified several CARC and CRAC motifs 
randomly distributed along the amino acid sequence of Kv1.3 (including N-terminal, transmembrane 
segments and the C-terminus of the channel) (52). Some of them overlapped with highly conservative 
residues of Kv channels such as the voltage sensor or the activation gate, others were located on the 
variable regions of the Kv1.3. Mutational analysis of the conservative regions would be problematic since 
it has been demonstrated that simple point mutations of identical parts of Shaker channel can cause non-
conducting channels (25, 32). On the contrary, relatively large perturbations in the distal C-terminus of the 
channel are well tolerated without a significant effect on the gating of Kv1.3 (57). Therefore, we decided 
to study a mutant Kv1.3 which lacks the putative cholesterol motifs of the distal C-terminal. Surprisingly, 
truncation of the distal C-terminus resulted in a phenotype that was resistant to the manipulation of CHOL 
and 7DHC content of the membrane (Figure 5). We propose that CARC motifs of the C-terminal interact 
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with membrane cholesterol of the inner leaflet via their hydrophobic residues and mediate sterol 
sensitivity of Kv1.3. A similar conclusion was reached by Robinson et al. who envisioned  that the C-
terminal of the P2X7 ion channel dips back into the plasma membrane and contacts the membrane via 
palmitoyl groups and hydrophobic residues (49). Further experiments including mutagenic scanning 
analysis of the putative C-terminal cholesterol recognition sites are necessary to reveal the exact 
identity/function of the CARC/CRAC domains of Kv1.3. It is also notable, that other members of the Kv 
family have distinct amino acid residues from Kv1.3 at equivalent positions, which do not fulfill the 
requirement of the CRAC or CARC pattern and thus, their sensitivity to sterols might be different. 
Furthermore, 7DHC, at identical loading concentrations, is more effective in changing the biophysical 
parameters of Kv1.3 gating than CHOL (Fig. 4). This may imply that the affinity of the sterol binding 
motif of Kv1.3 is different for CHOL and 7DHC and/or the bound sterols affect ion channel function 
differently (e.g., affecting  the coupling between the VSD and the PD through the activation gate of the 
channel which is located close to the sterol binding domains).  
SLOS T cells had the same current density as the age-matched control whereas “acute” in vitro 
7DHC elevation in the membrane decreased the current density, which can be accounted for by the 
suppression of the Kv1.3 current (Figure 1c and 3f). We think this discrepancy can be explained with the 
“exposure time” to 7DHC treatment: under in vivo circumstances, the cells can build up compensatory 
mechanisms resulting in the same whole-cell potassium conductance as for the control, while in vitro 
elevation of 7DHC level with its 60 min duration is not sufficient, e.g. to recruit new Kv1.3 channels into 
the plasma membrane. We found a similar phenomenon in our former study, where acute cholesterol 
treatment decreased the current density of Kv1.3, whereas hypercholesterinaemic T-cells had the same 
current density as the age-matched control (53). Currently we do not know either the nature of the 
reduction in the K
+
 conductance upon acute exposure of the cells to sterols or the origin of the putative 
compensatory mechanism. The suppression of the current may originate from a change in any one or a 
combination of three possible factors due to increased 7DHC/CHOL ratio: single channel current could 
decrease and/or open probability could decrease and/or number of channels could decrease. (13, 15, 52).  
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Several studies reported that the modification of the operation of ion channels due to inherited 
mutations, which is often hallmarked by the change in the equilibrium and kinetic parameters of activation 
(or inactivation), leads to diseases such as epilepsy (Kv1.2), episodic ataxia (Kv1.1) and long QT-
syndrome (Kv7.1 or KCNQ1) (1, 2, 55). We obtained similar changes in the biophysical parameters of 
Kv1.3 gating (slower activation kinetics and shift in the voltage-dependence of steady-state activation 
toward positive potentials) in SLOS T cells as in channelopathies listed above. This rightward shift in the 
voltage-dependence of steady-state activation can have pathophysiological consequences similar to the 
loss-of-function mutations. The more positive half-maximal voltage in SLOS T cells can lead to reduced 
activity of Kv1.3 channels under physiological conditions, which should appear in the cellular functions 
coupled to the activity of Kv1.3. Kv1.3 is a crucial voltage-gated ion channel of lymphocytes, its main 
function is the membrane potential control of T cells thereby providing constant driving force required for 
Ca
2+
 entry during T cell activation. Consequently, suppression of the function of Kv1.3 leads to impaired 
activation and proliferation (10). Our data is consistent with this: upregulation of CD154 expression (an 
early, Ca
2+
-signal dependent marker of T cell activation) upon activation of SLOS CD3
+
 T lymphocytes 
showed a significant reduction as compared to healthy donors (6, 62). Also, the “long-term effect” of 
modified operation of ion channels could be traced with the proliferation assay: SLOS cells tended to 
divide at a lower rate compared to control T cells, a phenomenon which was clearly shown for Kv1.3 
inhibitors (10, 63). The Ca
2+
-signaling-linked activation of T lymphocytes is a classic example of the 
interplay of ion channels, transporters and signaling molecules (see above) , reviewed in (22, 64). Even 
though the sterol sensitivity of Kv1.3 is a potential mechanism for the reduced T cell 
activation/proliferation we cannot exclude that the altered lipid milieu in SLOS affects other transporters 
and/or signaling molecules, which contribute to the altered T cell function in SLOS. Also we should not 
exclude the significance of the toxic effects of 7DHC and oxysterols (including 7DHC-derived 
oxysterols), which were shown earlier to hinder activation and/or proliferation of cells and cause retinal 
degeneration in a rat model of SLOS (21, 40, 68). It has been demonstrated that SLOS-derived fibroblasts 
show impaired Na/K pump function, increased Ca
2+
 permeability and reduced proliferation (61). These 
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data confirm our hypothesis, that altered function of various ion transporters, such as the hereby studied 
Kv1.3, can have functional consequences on the immune responses in SLOS. In mouse models of SLOS 
(7DHR-/- animals) it was recently reported that mast cells showed constitutive cytokine production and 
hyper-degranulation upon IgE receptor activation, which occurred due to the altered raft system of SLOS 
cell membrane. ((31)) Even though immunodeficiency was not recognized initially as a part of SLOS, two 
recent case reports described serious infections in these patients. They proposed immunodeficiency behind 
this phenomenon, which is consistent with the data regarding altered T-cell activation/proliferation (3, 9).  
In summary, we showed that changes in the biophysical properties of Kv1.3 channels in SLOS are 
due to the altered 7DHC/CHOL ratio, and the sterol–channel interaction is conveyed by sterol binding 
motifs on the channel. Furthermore, the modified operation of Kv1.3 influences the linked 
cellular/signaling processes, which can lead to the dysfunction of the cells. We also conclude that C-
terminus of Kv1.3 is highly involved in the sterol-mediated regulation of the channel. Significance of the 
two putative CHOL binding sites not clear yet, but this experiment implies their role in the regulation of 
Kv1.3.  
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Figure legends 
Figure 1 Expression level of Kv1.3 in SLOS (a) The average WCC (whole-cell current) and (b) 
C (whole-cell capacitance) and (c) CuD (current density) for the control and SLOS donors. Error 
bars represent SEM. 
 
Figure 2 Activation of Kv1.3 channels is modified in SLOS T cells (a) To study the kinetic 
properties of activation of Kv1.3  T cells were depolarized to +50 mV from –120 mV for 15 ms. 
Normalized current traces evoked in an SLOS and a control T cells are shown with the best-fit 
curves using Hodgkin-Huxley n
4-
modell (see Material and Methods). (b) To study the 
inactivation of the Kv1.3 current T cells were depolarized to +40 mV for 2 seconds from a 
holding potential of –120 mV. The representative current traces for a control and an SLOS cell 
are displayed with the best-fitting single exponential function to the declining phase of the curve 
(also detailed in the Material and Methods). (c). Voltage-dependence of equilibrium activation of 
the Kv1.3 channels in an SLOS (circle) and a healthy (triangles) T cell along with the best-fit 
Boltzmann functions is illustrated. The normalized conductance-test potential relationships 
(Gnorm-V plot) were obtained and analyzed as described in the Materials and Methods. (d and e) 
The activation (n=56, 8 donors for control; n=44, 8 patients for SLOS) and inactivation (n=38, 8 
donors for control; SLOS: n=45, 8 patients) time constants for Kv1.3 currents in SLOS and 
control T cells. (mean ± SEM, * represents statistical difference at p=0.05) . (f) Parameters of 
steady-state activation (slope (k) and midpoint (V1/2)) are shown for the Kv1.3 channels in SLOS 
and control T cells. (mean ± SEM, control: n=41, 8 donors; SLOS: n=38, 8 patients, *: statistical 
difference at p=0.05)). 
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Figure 3 7DHC loading mimics SLOS in T cells (a) GC-MS analysis of CHOL and 7DHC 
level in MCD/7DHC treated (65 and 195M) control lymphocytes (from healthy age-matched 
donors). 140 M MCD/CHOL treatment was applied as a positive control. (b) Current traces of 
Kv1.3 activation are shown for 7DHC-loaded cells, same protocol was applied as in Fig 2A. (c) 
Normalized conductance of Kv1.3 current is plotted as a function of the membrane-potential (see 
materials and methods and Fig 2c) for MCD/7DHC treated cells, the fitted Boltzmann curves 
are also shown. (d-e) The activation time constant and the parameters of equilibrium activation 
are shown (n>7 for each treatment). (f) Current density (CuD) of 7DHC loaded cells (mean ± 
SEM, n>7); * and ** indicate statistical difference at p=0.05 and p=0.01, respectively. 
 
Figure 4 Kv1.3 sensitivity to 7DHC- and CHOL-loading is different Control lymphocytes 
(from healthy age-matched donors) were loaded with 7DHC and CHOL at equal concentrations, 
and activation kinetics and voltage-dependence of steady-state activation were investigated as 
detailed in Figure 2a and c. (a, b, c): Average activation time constants of Kv1.3 current at 32.5, 
65 and 195 µM MCD/7DHC and MCD/CHOL concentrations. (d, e, f) Average of the half-
maximal voltage for equilibrium activation at treatment with 32.5, 65 and 195 µM MCD/7DHC 
and MCD/CHOL. Data are presented as mean ± SEM. * and ** represent significant difference 
at p=0.05 and p=0.001, respectively.  
 
Figure 5 Kv1.3 C-terminus are involved in the sterol mediated regulation. CHO cells stably 
expressing mGFP-Kv1.3-WT and mGFP-Kv1.3C channels were loaded with 7DHC and CHOL 
(both at 420 µM), and activation kinetics and voltage-dependence of steady-state activation were 
studied as detailed before in Figure 2a and c. (a, b): Average activation time constants for Kv1.3 
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current upon MCD/CHOL (a) and MCD/7DHC (b). (c-d) Average half-maximal voltage for 
steady-state activation upon CHOL (c) and 7DHC loading (d). Bar graphs show mean ± SEM for 
n>5. * and ** represent significant difference at p=0.05 and p=0.001, respectively. 
 
 
Figure 6 CD154 expression in SLOS is hampered (a, b) Representative dot-plots of flow 
cytometric measurement for SLOS (a) and healthy (b) PBMCs labeled with anti CD3-PE and 
anti-CD154-Alexa488 after a 3-hour-activation with thapsigargin (1 µM). (c) CD154 expression 
distribution of CD3
+
 T cells of a healthy and an SLOS donor upon thapsigargin activation 
(isotype control is also shown). (d) Mean percentage of CD154
+
CD3
+
 T cells in SLOS (n=5) and 
healthy (n=4) group (mean ± SEM is displayed, *: significant difference for p=0.05). 
 
Figure 7 Proliferation of T cells in SLOS is impaired (a and b) Dot-plots show the gating 
procedure for lymphocytes based on their light-scatter properties (SSC vs. FSC). Panel a shows 
the stimulated control PBMC population on day 0, and b displays the stimulated population on 
day 5 following activation: activated T cells have higher light scatter intensities and mainly dead 
cells are outside the gate. (c and d) CFSE fluorescence intensity histograms obtained for a 
healthy donor (c) and a representative SLOS sample (d). A marker was placed over the divided 
(D) and to the undivided cell (U.D.) subpopulations. (e) The ratio of divided cells and all gated 
cells is shown for SLOS (n=4) and control (n=4) group (data is represented as mean ± SEM, **:  
p=0.007) 
